The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
Fludarabine treatment in patients with B-cell chronic lymphocytic leukemia (B-CLL) can trigger or exacerbate the development of autoimmune hemolytic anemia (AHA) through a currently ill-defined mechanism. We here show that exposure of peripheral blood lymphocytes from healthy donors and B-CLL patients to fludarabine increases in vitro production of interferon-gamma, a key cytokine in the pathogenesis of AHA.
Romina
R
Gamberale
Paula
P
Fernández-Calotti
Julio
J
Sánchez-Avalos
María Fabiana
MF
Alberto
Jorge
J
Geffner
Mirta
M
Giordano
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced / Q000209:etiology; D016022:Case-Control Studies; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D007371:Interferon-gamma; D014740:Vidarabine; C024352:fludarabine